Plasma Adiponectin Concentration, Activity and Isoforms in Newly Diagnosed and Untreated Type 2 Diabetes Mellitus
Recruitment status was Recruiting
The objective of present study were to compare plasma adiponectin isoform status, their bioactivities newly diagnosed Chinese with healthy volunteer.
|Study Design:||Observational Model: Cohort
Time Perspective: Cross-Sectional
|Official Title:||Plasma Adiponectin Concentration, Activity and Isoforms in Newly Diagnosed and Untreated T2DM Patients in Chinese Population|
- plasma adiponectin concentration, isoform distribution and activity. [ Time Frame: participants will be followed for the duration of hospital stay, an expected average of 1 week ] [ Designated as safety issue: No ]
Biospecimen Retention: Samples Without DNA
blood，abdominal fat tissue
|Study Start Date:||May 2010|
|Estimated Study Completion Date:||December 2011|
|Estimated Primary Completion Date:||October 2011 (Final data collection date for primary outcome measure)|
newly diagnosed T2DM patients and untreated with any drugs.
|Non-diabetic Control Group|
Adiponectin, circulates as trimer, hexamer and high molecular weight form (HMW) in human blood, is a promising biomarker for indication diabetes and cardiovascular disease. Both adiponectin complexes concentration and their bioactivities are decreased in pathological state. Disulﬁde-bond A oxidoreductase-like protein (DsbA-L) is a key regulator for adiponectin biosynthesis and its expression level is down-regulated in obese mice and humans. However, the alteration of circulating adiponectin multimers distribution, their bioactivities and adiponectin regulator, DsbA-L level, in newly diagnosed Chinese type 2 diabetes patients are unknown. The objective of present study were to compare plasma adiponectin isoform status, their bioactivities and DsbA-L concentration in newly diagnosed Chinese with healthy volunteer.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01372852
|Contact: Ling Tao, M.D Ph.Demail@example.com|
|Xi'an, Shaanxi, China, 710032|
|Contact: Ling Tao, MD,PhD +86-15002955798 firstname.lastname@example.org|
|Principal Investigator:||Ling Tao, M.D Ph.D||Department of Cardiology of Xijing Hospital, Fourth Military Medical University|